GT Metabolic Solutions, Inc. announced an undisclosed Series C growth investment from J.P. Morgan Life Sciences Private Capital, a follow-on round for the Minneapolis-based company. The company is described as the first to receive FDA De Novo grant and 510(k) clearance for use of magnetic technology to create compression anastomoses. No metrics on revenue, clients, pipeline or employee count were disclosed in the provided excerpt, and the stated use of proceeds was truncated as supporting the Company's "ongoing glo..."